PA 522 Week 5 Axis Level Write-Up Example

Axis Level Write-Up: Placing M.T.'s Aldosterone Excess at the Adrenal Gland Itself, Arguing Against a Renin-Driven Cause and Leaving the Choice Between One Gland and Both for Adrenal Vein Sampling

Student Name

Chamberlain University

PA 522: Comprehensive Clinical Module Endocrinology

Instructor Name

Month Day, Year

Axis Level Write-Up: Placing M.T.'s Aldosterone Excess at the Adrenal Gland Itself, Arguing Against a Renin-Driven Cause and Leaving the Choice Between One Gland and Both for Adrenal Vein Sampling

Thesis

M.T.'s aldosterone excess arises in the adrenal cortex itself, independent of renin, and not from a renin-driven process upstream. That places the disorder at the gland level: primary aldosteronism. What the level does not settle is whether one gland or both are responsible.

Establishing the Level

Three findings carry the argument. First, the screening pair: aldosterone 16 ng/dL with renin activity 0.3 ng/mL/h, a ratio near 53, drawn while M.T. was taking lisinopril, a drug that should have raised renin. Second, the captopril challenge: aldosterone fell only from 18.2 to 16.9 ng/dL, about 7 percent, when a normal response is a fall of more than 30 percent, and renin stayed at 0.3 to 0.4 (Funder et al., 2016). Third, the potassium of 3.2 mmol/L before correction, with a urine potassium of 48 mmol/L on the same day, meaning the kidney was losing potassium despite a low blood level, which is what excess aldosterone does.

Cannot Respond Against Never Asked

The phrase matters here in a specific way. M.T.'s renin is low, but renin is not failing. It is being silenced by the expanded volume that the excess aldosterone produces, which is exactly what a healthy kidney should do. The gland making aldosterone, by contrast, is not answering a request at all; nothing is asking it to secrete, and it secretes anyway. The level of the disorder is the station that acts without being asked, not the station that has gone quiet.

The Leading Alternative, Argued Properly

The strongest alternative is secondary aldosteronism, in which something upstream drives renin and aldosterone follows. A narrowed renal artery is the commonest cause in a 61-year-old with resistant hypertension, and it can also cause low potassium. The alternative deserves a fair hearing: M.T. is a former smoker with high blood pressure on three medicines, the profile in which renal artery disease is found. But secondary aldosteronism predicts a high renin, and M.T.'s renin is suppressed, both before and after captopril. A renin-secreting tumor and diuretic use make the same prediction and are excluded on the same evidence; the thiazide had been stopped five weeks before the challenge.

The Distinguishing Test

The test that separates the two levels has already been done: renin. A renin above its interval would have placed the disorder upstream; a renin suppressed despite an ACE inhibitor and despite captopril places it at the gland. No renal artery imaging is needed to answer the level question, although M.T.'s CT, done for a kidney stone, showed no large narrowing of either renal artery.

What the Level Leaves Open

Primary aldosteronism can come from a single aldosterone-producing adenoma, often curable by removing that gland, or from both glands, treated with medicine. The CT shows a 2.6 cm left adrenal nodule and a normal-looking right gland, but CT does not reliably tell which gland is making aldosterone. In older patients, a nodule may be a non-secreting bystander while the excess comes from the other side or from both. The guideline therefore recommends adrenal vein sampling, done by an experienced radiologist, before surgery in patients who want a surgical option (Funder et al., 2016). Some centers skip sampling in younger patients with a clear unilateral nodule and very high aldosterone, but at 61 M.T. is past the age at which that shortcut is considered.

Vocabulary

The write-up uses primary aldosteronism for the gland-level disorder and reserves aldosterone-producing adenoma for a lesion proven to secrete, which has not been shown yet. It does not call the left nodule an aldosteronoma, because that would assume the answer to the open question.

The Parallel Questions

Two other findings in M.T.'s record could be mistaken for parts of this argument. The high calcium with a normal parathyroid hormone is a separate axis and is being investigated on its own; it does not bear on the level of the aldosterone problem. The thyroid results that looked like Graves disease are probably a biotin artifact and are being repeated. Neither changes the conclusion here, and the write-up keeps them out of the argument so that the evidence for the level is not padded with findings that do not support it.

Next Step Recorded

M.T. was asked about surgery and said yes, if one side is responsible. Adrenal vein sampling was requested at the regional center, with cosyntropin infusion during sampling per that center's protocol, and spironolactone was deferred until after sampling so it does not affect the results (Young, 2019).

References

Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F., Jr. (2016). The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 101(5), 1889-1916. https://doi.org/10.1210/jc.2015-4061

Young, W. F., Jr. (2019). Diagnosis and treatment of primary aldosteronism: Practical clinical perspectives. Journal of Internal Medicine, 285(2), 126-148. https://doi.org/10.1111/joim.12831